ArticleCureus2025
A Comparative Evaluation of the Efficacy and Safety Profile of Cariprazine and Olanzapine in Patients With Schizophrenia in a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Schizophrenia is a chronic psychiatric disorder requiring long-term antipsychotic treatment. Cariprazine, a newer atypical antipsychotic with D2/D3 partial agonist activity, has shown promise in managing both positive and negative symptoms. This study aimed to compare the efficacy and safety of cariprazine with olanzapine in patients with schizophrenia in a tertiary care setting in India. Methods A prospective comparative study was conducted among 60 patients diagnosed with schizophrenia, allocated in equal numbers to cariprazine and olanzapine groups. Baseline and six-week assessments were performed using the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), and the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale. Statistical analyses included t-tests, ANOVA, and chi-square tests, with significance set at p<0.05. Results Both groups showed significant improvements from baseline on BPRS, SAPS, and SANS scores (p<0.001). At six weeks, cariprazine was more effective in reducing negative symptoms (SANS: 39.90 ± 19.25) compared to olanzapine (SANS: 55.37 ± 16.22; p=0.005). Olanzapine led to a greater reduction in positive symptoms (SAPS: 38.13 ± 18.45 vs. 45.80 ± 20.33; p=0.008). UKU scores indicated minimal adverse effects in both groups, with cariprazine showing a slightly more favorable tolerability profile (2.97 ± 3.42 vs. 3.07 ± 3.63; p<0.001). Age significantly influenced BPRS outcomes, while gender, marital status, and socioeconomic status had no significant effect. Conclusion Both cariprazine and olanzapine demonstrated comparable overall efficacy. Cariprazine showed an advantage in improving negative symptoms and exhibited a more favorable side effect profile. Given the small sample size, short follow-up period, and single-center setting, these findings should be interpreted with caution. Larger, long-term trials are needed to confirm the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.